绝经后女性骨折预防药物疗法的疗效:网络荟萃分析
该网络荟萃分析纳入107项随机对照试验(193,987例绝经后骨质疏松女性),比较多种药物对髋部、椎体和非椎体骨折的预防效果。结果显示特立帕肽、阿巴洛肽、地舒单抗和罗莫索单抗相对风险降低最高,而伊班膦酸和选择性雌激素受体调节剂疗效较低。
要点
- 罗莫索单抗、阿仑膦酸、唑来膦酸、利塞膦酸、地舒单抗、雌孕激素联合及钙+维生素D显著降低髋部骨折风险。
- 特立帕肽、阿巴洛肽、地舒单抗和罗莫索单抗相对风险降低最高,伊班膦酸和SERM较低。
- 维生素D和钙预防骨折的证据仍然有限。
核心结论
- 该网络荟萃分析提供了多种可用治疗降低绝经后女性脆性骨折风险的比较效果估计。
研究设计与样本
- 检索MEDLINE、EMBASE、Cochrane Central、ISI Web of Science和Scopus的随机对照试验,纳入绝经后原发性骨质疏松女性,评估髋部、椎体或非椎体骨折风险,采用多变量随机效应方法进行网络荟萃分析。
- 共纳入107项试验,193,987例绝经后女性,平均年龄66岁,55%为白人,中位随访28个月。
主要发现
- 罗莫索单抗、阿仑膦酸、唑来膦酸、利塞膦酸、地舒单抗、雌孕激素联合及钙+维生素D显著降低髋部骨折风险。
- 阿巴洛肽、罗莫索单抗、地舒单抗、特立帕肽、阿仑膦酸、利塞膦酸、唑来膦酸、拉索昔芬、替勃龙、雌孕激素联合及维生素D显著降低非椎体骨折风险。
- 阿巴洛肽、特立帕肽、甲状旁腺激素1-84、罗莫索单抗、雷奈酸锶、地舒单抗、唑来膦酸、利塞膦酸、阿仑膦酸、伊班膦酸、雷洛昔芬、巴多昔芬、拉索昔芬、雌孕激素联合、替勃龙及降钙素显著降低椎体骨折风险。
- 特立帕肽、阿巴洛肽、地舒单抗和罗莫索单抗相对风险降低最高,伊班膦酸和选择性雌激素受体调节剂疗效较低。
- 维生素D和钙治疗骨折的证据仍然有限,尽管已有许多大型试验。
临床怎么用
- 对于绝经后骨质疏松女性,可根据骨折类型选择证据支持的药物进行个体化预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteoporosis and osteopenia are associated with increased fracture incidence in postmenopausal women. We aimed to determine the comparative effectiveness of various available pharmacological therapies. METHODS: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, ISI Web of Science, and Scopus for randomized controlled trials that enrolled postmenopausal women with primary osteoporosis and evaluated the risk of hip, vertebral, or nonvertebral fractures. A network meta-analysis was conducted using the multivariate random effects method. RESULTS: We included 107 trials (193,987 postmenopausal women; mean age, 66 years; 55% white; median follow-up, 28 months). A significant reduction in hip fractures was observed with romosozumab, alendronate, zoledronate, risedronate, denosumab, estrogen with progesterone, and calcium in combination with vitamin D. A significant reduction in nonvertebral fractures was observed with abaloparatide, romosozumab, denosumab, teriparatide, alendronate, risedronate, zoledronate, lasofoxifene, tibolone, estrogen with progesterone, and vitamin D. A significant reduction in vertebral fractures was observed with abaloparatide, teriparatide, parathyroid hormone 1-84, romosozumab, strontium ranelate, denosumab, zoledronate, risedronate, alendronate, ibandronate, raloxifene, bazedoxifene, lasofoxifene, estrogen with progesterone, tibolone, and calcitonin. Teriparatide, abaloparatide, denosumab, and romosozumab were associated with the highest relative risk reductions, whereas ibandronate and selective estrogen receptor modulators had lower efficacy. The evidence for the treatment of fractures with vitamin D and calcium remains limited despite numerous large trials. CONCLUSIONS: This network meta-analysis provides comparative effective estimates for the various available treatments to reduce the risk of fragility fractures in postmenopausal women.
引用
- Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. J Clin Endocrinol Metab. 2019. PMID: 30907957. doi:10.1210/jc.2019-00192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。